Drug Profile
Research programme: antipsychotic therapies - Mitsubishi Pharma/YRING
Alternative Names: Antipsychotic therapies research programme - Mitsubishi Pharma/YRINGLatest Information Update: 26 Sep 2006
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation; University of Glasgow; University of Strathclyde; Yoshitomi Research Institute of Neuroscience in Glasgow
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 26 Sep 2006 No development reported - Preclinical for Schizophrenia in Scotland (unspecified route)
- 03 Mar 2003 Preclinical trials in Schizophrenia in Scotland (unspecified route)